Momenta Pharmaceuticals

Momenta Pharmaceuticals, Inc. is a biotechnology company specializing in the characterization and process engineering of complex molecules. These complex molecules include proteins, polypeptides, and cell surface polysaccharides, such as heparan-sulfate proteoglycans. This results in a diversified product pipeline of complex generic, follow-on biologic and novel drugs. The Company's two most advanced complex generic product candidates target marketed products, which were originally approved by the United States Food and Drug Administration as New Drug Applications. M-Enoxaparin is designed to be a generic version of Lovenox (enoxaparin sodium injection), a low-molecular weight heparin used to prevent and treat deep vein thrombosis. Its second major generic product candidate is M356, a generic version of Copaxone (glatiramer acetate injection), a drug that is indicated for the reduction of the frequency of relapses in patients with relapsing-remitting multiple sclerosis.
Show more

Employee Rating

4.1More
TypeSubsidiary
Parent CompanyJohnson & Johnson
HQCambridge, MA, US
Founded2001
Websitemomentapharma.com
Momenta Pharmaceuticals was founded in 2001 and is headquartered in Cambridge, MA, US

Viewing summary data as a guest

Sign up for free to see all data
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at Momenta Pharmaceuticals

Santiago Arroyo

Santiago Arroyo

Senior Vice President, Development and Chief Medical Officer
Alejandra Carvajal

Alejandra Carvajal

Chief Legal Officer and General Counsel
Ian D. Fier

Ian D. Fier

Chief Operating Officer
Young Kwon

Young Kwon

Chief Financial and Business Officer
Anthony Manning

Anthony Manning

Chief Scientific Officer
Jo-Ann Beltramello

Jo-Ann Beltramello

Chief Human Resources and Infrastructure Officer
Show more

Momenta Pharmaceuticals Office Locations

Momenta Pharmaceuticals has offices in Cambridge and Dublin
Cambridge, MA, US (HQ)
301 Binney St
Cambridge, MA, US
320 Bent St
Dublin, IE
Regus House, Harcourt Centre, Harcourt Rd, Saint Kevin's
Show all (3)

Momenta Pharmaceuticals Financials and Metrics

Summary Metrics

Founding Date

2001
Momenta Pharmaceuticals is a subsidiary of Johnson & Johnson

Momenta Pharmaceuticals Revenue

Momenta Pharmaceuticals's revenue was reported to be $23.87 m in FY, 2019
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Revenue

283.1m63.9m35.5m52.3m89.7m109.6m138.9m75.6m23.9m

General and administrative expense

38.7m43.7m41.1m45.2m48.1m64.5m82.2m149.8m

R&D expense

64.7m80.3m104.0m106.5m126.0m119.9m149.2m124.0m144.5m

Operating expense total

103.4m124.0m145.1m151.6m174.1m184.3m231.4m209.1m335.6m
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Cash

49.2m53.0m29.8m191.5m61.5m150.7m73.7m248.3m382.5m

Accounts Receivable

28.2m10.8m13.1m7.4m19.4m15.0m11.4m8.0m

Prepaid Expenses

2.5m5.0m3.4m3.5m3.5m6.8m6.3m9.5m

Inventories

4.6m
USDQ2, 2011

Financial Leverage

1 x
Show all financial metrics

Momenta Pharmaceuticals Online and Social Media Presence

Embed Graph

Momenta Pharmaceuticals News and Updates

Momenta Pharmaceuticals Announces Completion of Proposed Sale to Johnson & Johnson

CAMBRIDGE, Mass., Oct. 01, 2020 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA, “Momenta” or the “Company”), a biotechnology company focused on discovering and developing novel biologic therapeutics to treat rare immune-mediated diseases, today announced the successful completion …

Johnson & Johnson Completes Acquisition of Momenta Pharmaceuticals, Inc.

NEW BRUNSWICK, N.J., Oct. 1, 2020 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced it has successfully completed its acquisition of Momenta Pharmaceuticals, Inc. ("Momenta"), a company that discovers and develops novel therapies for immune-mediated diseases, in an all cash...

Momenta Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period in Connection with Proposed Sale to Johnson & Johnson

CAMBRIDGE, Mass., Sept. 15, 2020 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA, “Momenta” or the “Company”), a biotechnology company focused on discovering and developing novel biologic therapeutics to treat rare immune-mediated diseases, today announced the expiration of the wai…

SHAREHOLDER ALERT: WeissLaw LLP Investigates Momenta Pharmaceuticals, Inc.

NEW YORK, Aug. 19, 2020 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Momenta Pharmaceuticals, Inc. ("MNTA" or the "Company") (NASDAQ: MNTA) in connection with the proposed acquisition of the...

Momenta Pharmaceuticals soars after $6.5 billion buyout deal with J&J

Momenta Pharmaceuticals soars after $6.5 billion buyout deal with J&J

Johnson & Johnson to Acquire Momenta Pharmaceuticals, Inc., Expanding Janssen's Leadership in Novel Treatments for Autoimmune Diseases

NEW BRUNSWICK, N.J., Aug. 19, 2020 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) today announced it has entered into a definitive agreement to acquire Momenta Pharmaceuticals, Inc. (Momenta), a company that discovers and develops novel therapies for immune-mediated diseases, in an all cash...
Show more

Momenta Pharmaceuticals Blogs

Momenta Pharmaceuticals Appoints Dr. Jane F. Barlow to Board of Directors

CAMBRIDGE, Mass. , Dec. 13, 2019 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA) today announced the appointment of Jane F. Barlow , M.D., M.P.H., M.B.A. to its Board of Directors. “Dr. Barlow’s expertise in market access and commercial pricing will be invaluable as we continue to

Momenta Pharmaceuticals Announces Pricing of Public Offering of Common Stock

CAMBRIDGE, Mass. , Dec. 12, 2019 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA) today announced the pricing of its underwritten public offering of 14,516,130 shares of its common stock at the public offering price of $15.50 per share for total gross proceeds to Momenta of

Momenta Pharmaceuticals Announces Proposed Public Offering of Common Stock

CAMBRIDGE, Mass. , Dec. 10, 2019 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA) today announced that it is commencing an underwritten registered public offering of $200,000,000 of shares of its common stock. Momenta also expects to grant the underwriters of the offering an option

Momenta Pharmaceuticals Announces Poster Presentation at the 61st American Society of Hematology Annual Meeting and Exposition

CAMBRIDGE, Mass. , Nov. 07, 2019 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA) today announced that Santiago Arroyo , M.D., Ph.D., Chief Medical Officer, will deliver a poster presentation at the upcoming 61 st American Society of Hematology (ASH) Annual Meeting and Exposition

Momenta Pharmaceuticals to Webcast Presentation at Two Upcoming Investor Conferences

CAMBRIDGE, Mass. , Nov. 06, 2019 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA), a biotechnology company focused on discovering and developing novel biologic therapeutics to treat rare immune-mediated diseases, today announced that it will webcast its presentation at two upcoming

Momenta Pharmaceuticals Announces Date of Third Quarter 2019 Financial Results Conference Call and Webcast

Momenta Pharmaceuticals Announces Date of Third Quarter 2019 Financial Results Conference Call and Webcast Content Import Thu, 10/17/2019 - 08:02 Momenta Pharmaceuticals Announces Date of Third Quarter 2019 Financial Results Conference Call and Webcast Oct 17, 2019 …
Show more

Momenta Pharmaceuticals Frequently Asked Questions

  • When was Momenta Pharmaceuticals founded?

    Momenta Pharmaceuticals was founded in 2001.

  • Who are Momenta Pharmaceuticals key executives?

    Momenta Pharmaceuticals's key executives are Santiago Arroyo, Alejandra Carvajal and Ian D. Fier.

  • How many employees does Momenta Pharmaceuticals have?

    Momenta Pharmaceuticals has 118 employees.

  • What is Momenta Pharmaceuticals revenue?

    Latest Momenta Pharmaceuticals annual revenue is $23.9 m.

  • What is Momenta Pharmaceuticals revenue per employee?

    Latest Momenta Pharmaceuticals revenue per employee is $202.3 k.

  • Who are Momenta Pharmaceuticals competitors?

    Competitors of Momenta Pharmaceuticals include Dermavant Sciences, Kuros Biosciences and Olainfarm.

  • Where is Momenta Pharmaceuticals headquarters?

    Momenta Pharmaceuticals headquarters is located at 301 Binney St, Cambridge.

  • Where are Momenta Pharmaceuticals offices?

    Momenta Pharmaceuticals has offices in Cambridge and Dublin.

  • How many offices does Momenta Pharmaceuticals have?

    Momenta Pharmaceuticals has 3 offices.